Genprex Inc (NASDAQ:GNPX), a clinical-stage gene-therapy company, announced Thursday that CEO Rodney Varner will present at the Singular Research Summer Solstice 2018 in New York City.
Varner will be presenting Thursday at 10.40 am ET at the high-profile conference in the small- and micro-cap space.
The Austin, Texas-based biopharmaceutical company is making great strides toward developing its non-small-cell, lung cancer-fighting, gene-therapy drug Oncoprex.
Varner earlier told Proactive Investors that Oncoprox is in Phase 2 of clinical trials, and next steps are to meet with the FDA about best pathways forward to an approval.
The company recently went public, raising $6.4mln. Varner said the biopharma will use the funds to continue clinical trials and expand and/or accelerate development programs into additional drug combinations.
Investors will be tuning into the conference for more details about progress on Oncoprox.
Investor excitement about the lung cancer-fighting, gene-therapy drug sent Genprex stock more than 1% higher to US$7.39 on Thursday's premarket action.
Contact Uttara Choudhury at [email protected]